文献速递艾滋病与性传播感染

非洲HIV感染儿童二线治疗中每日一次达芦那韦/利托那韦的药代动力学

Pharmacokinetics of once-daily darunavir/ritonavir in second-line treatment in African children with HIV.
PubMed 文献 · J Antimicrob Chemother · 2024-01-01

在CHAPAS-4药代动力学亚研究中,59名非洲HIV感染儿童接受每日一次达芦那韦/利托那韦(14-24.9 kg用600/100 mg,≥25 kg用800/100 mg)二线治疗,达芦那韦AUC0-24h和Cmax高于成人参考值,Ctrough与成人相当,核苷类逆转录酶抑制剂骨架不影响达芦那韦浓度,模拟WHO推荐剂量暴露与成人等效。

要点

  • 达芦那韦在非洲HIV感染儿童中暴露在安全范围内
  • 达芦那韦/利托那韦可与TAF/FTC安全联用
  • WHO推荐600/100 mg与CHAPAS-4的800/100 mg在25-34.9 kg体重组均提供有利暴露

核心结论

  • 本试验中达芦那韦暴露在安全范围内,达芦那韦/利托那韦可与TAF/FTC安全联用。
  • WHO推荐的600/100 mg与CHAPAS-4的800/100 mg达芦那韦/利托那韦剂量在25-34.9 kg体重组均提供有利暴露,选择可取决于片剂可及性。

研究设计与样本

  • CHAPAS-4嵌套药代动力学亚研究,纳入59名非洲HIV感染儿童,中位年龄10.9岁(范围3.8-14.7),中位体重26.0 kg(范围14.5-47.0)。
  • 每日一次达芦那韦/利托那韦剂量为14-24.9 kg用600/100 mg,≥25 kg用800/100 mg,联用TAF/FTC、阿巴卡韦/拉米夫定或齐多夫定/拉米夫定。
  • 稳态药代动力学采样于观察到达芦那韦/利托那韦摄入后0、1、2、4、6、8、12和24小时进行,采用非房室和群体药代动力学分析。
  • 使用参考成人药代动力学数据进行比较,并模拟WHO推荐的25-34.9 kg体重组600/100 mg达芦那韦/利托那韦剂量。

主要发现

  • 两室处置模型加转运吸收房室和基于体重的清除率与容积异速增长最佳描述达芦那韦数据。
  • 本群体达芦那韦AUC0-24h几何均值(%CV)为94.3(50)mg·h/L,Cmax为9.1(35)mg/L,高于成人参考值;Ctrough为1.5(111)mg/L,与成人值相当。
  • 核苷类逆转录酶抑制剂骨架未发现影响达芦那韦浓度。
  • 模拟的WHO推荐达芦那韦/利托那韦剂量显示暴露与成人等效。
  • 较高的α1-酸性糖蛋白增加达芦那韦结合并降低达芦那韦表观清除率。

临床怎么用

  • 作者结论认为达芦那韦/利托那韦可与TAF/FTC安全联用。
  • 作者结论认为WHO推荐600/100 mg与CHAPAS-4的800/100 mg达芦那韦/利托那韦剂量在25-34.9 kg体重组均提供有利暴露,选择可取决于片剂可及性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Darunavir is a potent HIV protease inhibitor with a high barrier to resistance. We conducted a nested pharmacokinetic sub-study within CHAPAS-4 to evaluate darunavir exposure in African children with HIV, taking once-daily darunavir/ritonavir for second-line treatment. METHODS: We used data from the CHAPAS-4 pharmacokinetic sub-study treating children with once-daily darunavir/ritonavir (600/100 mg if 14-24.9 kg and 800/100 mg if ≥25 kg) with either tenofovir alafenamide fumarate (TAF)/emtricitabine (FTC), abacavir/lamivudine or zidovudine/lamivudine. Steady-state pharmacokinetic sampling was done at 0, 1, 2, 4, 6, 8, 12 and 24 hours after observed darunavir/ritonavir intake. Non-compartmental and population pharmacokinetic analyses were used to describe the data and identify significant covariates. Reference adult pharmacokinetic data were used for comparison. We simulated the World Health Organization (WHO) recommended 600/100 mg darunavir/ritonavir dose for the 25-34.9 kg weight band. RESULTS: Data from 59 children with median age and weight 10.9 (range 3.8-14.7) years and 26.0 (14.5-47.0) kg, respectively, were available. A two-compartment disposition model with transit absorption compartments and weight-based allometric scaling of clearance and volume best described darunavir data. Our population achieved geometric mean (%CV) darunavir AUC0-24h, 94.3(50) mg·h/L and Cmax, 9.1(35) mg/L, above adult reference values and Ctrough, 1.5(111) mg/L, like adult values. The nucleoside reverse-transcriptase inhibitor backbone was not found to affect darunavir concentrations. Simulated WHO-recommended darunavir/ritonavir doses showed exposures equivalent to adults. Higher alpha-1-acid glycoprotein increased binding to darunavir and decreased apparent clearance of darunavir. CONCLUSIONS: Darunavir exposures achieved in our trial are within safe range. Darunavir/ritonavir can safely be co-administered with TAF/FTC. Both WHO-recommended 600/100 mg and CHAPAS-4 800/100 mg darunavir/ritonavir doses for the 25-34.9 kg weight band offer favourable exposures. The choice between them can depend on tablet availability.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Tsirizani L, Mohsenian Naghani S, Waalewijn H, et al. Pharmacokinetics of once-daily darunavir/ritonavir in second-line treatment in African children with HIV. J Antimicrob Chemother. 2024. PMID: 39302766. doi:10.1093/jac/dkae319

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。